Mr. Dennis Hancock reports

MOUNTAIN VALLEY MD ANNOUNCES APPOINTMENT OF ADVISORS AND STOCK OPTION GRANTS

Mountain Valley MD Holdings Inc. has appointed multiple advisers to the company as well as granted stock options to certain directors, officers and consultants/advisers of the company.

Appointment of advisers

The company has appointed the individuals listed below as advisers to provide strategic advisory services on customary commercial terms, with any compensation subject to applicable securities laws and the policies of the Canadian Securities Exchange.

"I am very pleased to welcome this group of advisers to MVMD," commented Dennis Hancock, president and chief executive officer of Mountain Valley MD. "Their collective experience across human health, agriculture, formulation science and capital markets aligns directly with our strategic priorities. As we continue to advance technologies in areas such as peptides and repurposed therapeutics, including emerging commercialization opportunities, we believe this group significantly strengthens our ability to execute and build long-term value."

Aubrey Marcus

Founder of Onnit, which he scaled to a nine-figure exit, and a recognized leader in human performance and wellness, Mr. Marcus is a New York Times bestselling author and host of a widely followed podcast, with a demonstrated ability to translate emerging health technologies into broad consumer adoption. His experience in branding, storytelling and distribution, combined with an extensive network across entrepreneurs, athletes and investors, supports strategic partnerships, capital alignment and market positioning.

Bode Miller

Olympic gold medalist and one of the most decorated alpine skiers in history, known for precision, resilience and elite performance, Mr. Miller has expanded into entrepreneurship, agriculture and wellness, with direct involvement in farming and land-based systems. He brings a practical perspective on performance optimization and agricultural innovation, along with relationships across sports, investment and regenerative food systems.

Shawn Wells

Widely regarded as a leading formulator in the nutraceutical industry, Mr. Wells is a nutritional biochemist behind numerous commercially successful ingredients and products. He holds multiple patents across ingredients and formulations and has worked with many global supplement brands. His expertise in bioavailability, ingredient innovation, peptide science and regulatory strategy supports product development and scalability, with a focus on optimizing stability, delivery systems and real-world efficacy.

Emily Kaplan

Ms. Kaplan is an entrepreneur, operator and strategic communications expert operating at the intersection of health innovation, science literacy and business growth. As chief executive officer and co-founder of MetFix, a national network of more than 150 brick-and-mortar affiliate locations deploying evidence-informed metabolic health protocols and the Broken Science Initiative, she has built a two-pronged platform addressing the root cause of the chronic disease epidemic. As founder of The Kleio Group, she advises politicians, celebrities and chief executive officers through crisis, launch and strategic pivots. A two-time HarperCollins business author and former producer for ABC News' 20/20, Primetime and Good Morning America, she has been featured in The Wall Street Journal and The New York Times. Ms Kaplan brings two decades of experience translating complex science and high-stakes narratives into clear, actionable strategy. She is a recognized voice in performance health and alternative health ecosystems, known for identifying early-stage breakthroughs and the influence to move them forward.

Dr. Janet Zand

Dr. Zand is a pioneer in integrative medicine with decades of experience combining conventional and complementary therapies. She has been actively involved in exploring and advancing repurposed therapeutics, within broader treatment frameworks. She is a co-founder and formulator for Zand Formulas, Humann and Pure BioHealth. She was the lead researcher on the first published, researched nitric oxide nutraceutical, which now has had over 1.5 million doses. Dr. Zand brings seasoned clinical expertise, regulatory awareness and a patient-centred approach, strengthening the company's credibility across both medical and consumer health landscapes.

Mark Gelnaw

Mr. Gelnaw is a senior financial executive with more than 35 years of experience in financial management, corporate strategy, and business leadership. He has served as chief operating officer of Deutsche Bank and chief operating and financial officer at Lehman Brothers and held senior roles at Salomon Brothers and Arthur Andersen. He also acted as chief executive officer and chief financial officer of Cynvec LLC, a cancer research company partnered with NYU (New York University). Mr. Gelnaw sits on numerous business advisory boards for both profit and non-profit organizations and is the founder of Breakwater Ventures, which manages investments across multiple sectors including health care, technology and financial services.

Alex Wolfe

Mr. Wolfe is a founder, operator and brand builder with over 12 years of experience in regulated and emerging markets, including psychedelics and nutraceuticals. As the founder of Eons, a global health and wellness company focused on functional-mushroom-based products, he works to combine adaptogenic compounds with advanced biotechnology platforms, including Mountain Valley MD's Quicksome technology, to support the development of differentiated consumer health products. He brings experience in business development, commercialization and market positioning, with a focus on scaling innovative technologies in high-growth categories.

Dr. Dan Engle

Dr. Engle is a board-certified psychiatrist with expertise in integrative mental health and emerging therapeutic approaches, including psychedelic-assisted therapy. He has extensive experience working with trauma, veterans and high-performance individuals, bridging conventional psychiatry with evolving treatment modalities. Dr. Engle contributes clinical perspective, ethical oversight and domain expertise in neurological and mental health innovation.

Domingos S.S. Junior

Mr. Junior is the founder and lead investor at DSJ Capital, a U.S.-based private equity firm. He brings more than two decades of experience across pharmaceutical, cosmetic, food and medical device industries, with deep expertise in regulatory affairs, quality systems and manufacturing operations. Mr. Junior previously served for over 20 years at Anvisa as a senior regulatory affairs specialist, with experience in GMP (good manufacturing practice) inspections, regulatory policy and international co-ordination, including participation in ICH forums. His background supports regulatory strategy, manufacturing scale-up and international market development.

Luis Felipe Scarpa Street

Mr. Scarpa is an investor and entrepreneur with over 25 years of experience across financial services, biotechnology and industrial ventures. He co-founded and managed a Brazilian hedge fund later acquired by Bradesco and has held executive leadership roles in marketing and business development. He is currently chief business development officer at Tecbio and co-founder of Biogrowth do Brasil. His experience spans capital markets, biotechnology commercialization and industrial applications, supporting business capitalization and strategic growth initiatives.

Stock option grant

The company also announces that, pursuant to the company's stock option plan, an aggregate 15.1 million incentive stock options have been granted to certain directors, officers and consultants/advisers of the company at an exercise price of six cents per share. The options are exercisable for a period of five years, with 20 per cent vesting on the date of grant, 30 per cent vesting on the six-month anniversary following the date of grant and the remaining 50 per cent vesting on the 12-month anniversary following the date of grant. Any securities issued upon exercise of the options will be subject to any applicable resale restrictions under CSE policies and securities laws.

"The granting of stock options is an important component of our approach to aligning our team and advisers with long-term shareholder value," commented Dennis Hancock, president and chief executive officer of Mountain Valley MD. "This structure allows us to preserve cash while ensuring that those contributing to the company's progress are directly incentivized alongside our shareholders as we continue to execute on our strategic priorities."

About Mountain Valley MD Holdings Inc.

Mountain Valley MD is building a world-class organization centred around the implementation, licensing and reselling of key technologies and formulations:

• Patented Quicksome oral formulation and delivery technologies;
• Patented Quicksol solubility formulation technology;
• Licensed product reseller of Agrarius, a novel agricultural plant signalling technology.

Consistent with its vision toward "More Life," Mountain Valley MD applies its owned and licensed technologies to its work for advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety and more. Additionally, Mountain Valley MD's work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage.

Mountain Valley MD's patented Quicksome technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy.

Mountain Valley MD's patented Quicksol technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally.

Mountain Valley MD's licensed Agrarius agricultural plant signalling technology is designed to be applied to crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change.

We seek Safe Harbor.